A Sr 2+ -SAPO-34 bed was assembled to study CO 2 dynamic adsorption under conditions that emulate those found in closed volume and portable applications. Although the surface area was reduced by 7% during pelletization, adsorption capacities estimated from breakthrough curves compared well with static volumetric adsorption data. Modeling of the breakthrough adsorption was achieved using a Linear Driving Force mass transfer rate model, showing good agreement with the experimental data and confirming fast kinetics and efficient use of the bed. Fast kinetics were also evidenced by the length of the unused section of the bed as calculated from a Mass Transfer Zone model. Adsorption capacity degradation was not observed after multiple regeneration cycles. Apparent and equilibrium adsorption isotherm data estimated from the bed and static volumetric experiments at 25 C were compared to that of 5A Zeolite. These showed that Sr 2+ -SAPO-34 is a superior adsorbent for CO 2 removal in the low partial pressure range (<1500 ppm). CO 2 and H 2 O multicomponent adsorption breakthrough curves were also gathered for a CO 2 inlet concentration of 1000 ppm and dew points of −5 and 8 C. The addition of moisture resulted in a decrease in total processed gas volume by 31 and 47%, respectively.

No abstract

No abstract

No abstract

Background: Appropriate pain control is one of the cornerstones necessary to promote positive clinical outcomes. A new bupivacaine liposomal formulation was designed to extend its analgesic effect for up to 72-hours post-surgery, reportedly leading to significant opioid-sparing. Method: Retrospective and prospective chart review conducted in a 178-bed academic institution between January 2013 to December 2013 and August 2014 to November 2014, in 115 patients that receive hip and knee arthroplasty. The primary outcome was the measurement of average daily pain score on post-operative days 1 and 2. Secondary outcomes included length of stay, overall opioid use post-surgery and pain control satisfaction using Press-Ganey® scores. Results: The average pain scores in the HCl group were 4.64 and 4.38 (Likert score: 0-10) for POD 1 and POD 2, compared to 4.72 POD 1 and 4.2 POD 2 in the liposome group (POD 1: p = 0.413; POD 2: p = 0.303). The difference in LOS for knee arthroplasty was statistically significant [HCl group: 1.94 days (± 0.66) versus liposome group: 2.27 days (±0.77) p-value = 0.038)] favoring the standard of care. For hip arthroplasty or bilateral knee arthroplasty the differences in LOS were not statistically significant ( p = 0.052 and p = 0.484 respectively). 93% of the patients in the HCl group, pain was well controlled, versus 88.5% in the liposome group with similar oxycodone IR use among groups. Conclusion: Liposome bupivacaine did not offer a notable benefit compared to the HCl formulation in our study.